Patients’ value of vaccine efficacy outweighs side effect concerns, Stanford study shows

The rate at which a vaccine protects against COVID-19 appears to be the strongest factor in deciding whether to get vaccinated, according to research published in the March issue of PNAS.

Advertisement

Stanford (Calif.) Medicine researchers surveyed more than 1,000 people across the U.S. in August and December, presenting scenarios of varying vaccine efficacy, minor side effects and severe adverse reactions. 

If vaccine efficacy is at least 70 percent, people are more likely to get vaccinated, the findings showed.

At the same time, minor side effects such as fever or a sore arm had little influence on respondents’ likelihood of getting vaccinated. Serious side effects including anaphylaxis or temporary paralysis swayed respondents toward not getting the vaccine if the chances of developing the reactions were relatively high, such as 1/100,000, but had little effect when the chances were 1/1 million or 1/100 million. 

To view the full findings, click here. 

More articles on public health:
Severely sick newborn with new COVID-19 variant had 51,418X higher viral load
COVID-19 hospitalizations by state: Feb. 24
J&J’s vaccine is safe, FDA says; California variant more contagious, early research shows — 7 COVID-19 updates

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The 2 KPIs that drive readmissions — and how hospitals act on them in real time

Tuesday, August 11
1:00 PM - 2:00 PM CDT

Presenter: Nik Rao, Dexur

Advertisement

Next Up in Public Health

Advertisement

Comments are closed.